Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06314698
Other study ID # IIT-2024-0011
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date April 1, 2024
Est. completion date April 30, 2027

Study information

Verified date March 2024
Source RenJi Hospital
Contact Honghui Huang, M.D.
Phone 00862168383141
Email honghui_huang@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if narlumosbart is non-inferior to denosumab in the treatment of bone diseases from multiple myeloma (MM).


Description:

Multiple myeloma is a plasma cell dyscrasia with a high likelihood of causing bone disease (ie, multiple myeloma-related bone disease); as a result, up to 80% of patients with newly diagnosed multiple myeloma present with osteolytic lesions. Denosumab is recommended for the treatment of newly diagnosed multiple myeloma, and for patients with relapsed or refractory multiple myeloma with evidence of multiple myeloma-related bone disease. Narlumosbart is a recombinant, fully human, anti-receptor activator of nuclear factor kappa-Β ligand (RANKL) IgG4 monoclonal antibody. Changing the IgG2 Fc portion of denosumab to IgG4, results in increased stability, higher specificity and affinity for RANKL than denosumab. The objective of this phase III trial is to compare the efficacy and safety between Narlumosbart and denosumab in patients with bone diseases from newly diagnosed multiple myeloma.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 478
Est. completion date April 30, 2027
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subjects fully understand and voluntarily participate in this study and sign the informed consent; 2. Age=18, no gender limitation; 3. Active multiple myeloma patients with newly diagnosed by International Myeloma Working Group (IMWG) 2014 criteria; 4. Measurable lesion per at least one of the following criteria : Serum monoclonal protein =10 g/L; Urinary monoclonal protein =200 mg/24h; Serum free Light Chain (FLC) assay showed an involved FLC level =100 mg/L with abnormal ratio for FLC (?/?); 5. Radiographic [X-ray, computer tomography (CT), magnetic resonance imaging (MRI), positons emission tomography coupled with a computer tomography (PET-CT)] evidence of at least one lytic bone lesion; 6. Plan to receive primary frontline anti-myeloma therapies, or receiving less than one cycle of frontline anti-myeloma therapy (less than 30 days, does not include radiotherapy or a single short course of steroid), the treatment regimens were limited to VRd, D-VRd, DRd, and VCd; 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 8. Adequate organ function, as defined by the following criteria (per laboratory values): 1. Liver function: Serum total bilirubin = 2.0 x upper limit of normal (ULN), Serum alanine aminotransferase = (ALT) 2.0 x ULN, Serum aspartate aminotransferase (AST) = 2.0 x ULN 2. Renal function: Serum creatinine clearance (CrCL) = 30 mL/min, calculated by the Cockcroft-Gault formula 3. Serum calcium or albumin-adjusted serum calcium =2.0 mmol/L (8.0 mg/dL) and = 2.9 mmol/L (11.5 mg/dL) 9. Reproductive potential subjects should be receiving effective contraception (Both male and female reproductive potential subjects, from the date of signing the informed consent to 6 months after the end of treatment); 10. Expected survival time = 3 months; Exclusion Criteria: 1. POEMS syndrome; 2. Plasma cell leukemia; 3. Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw; Non-healed dental/oral surgery, including tooth extraction; Active dental or jaw condition which requires oral surgery; Planned invasive dental procedures; 4. Planned radiation therapy or Orthopedic surgery; 5. Prior administration of denosumab or bisphosphonates; 6. Patients with active bone metabolic diseases (Paget disease of bone, Cushing syndrome and hyperprolactinemia), rheumatoid arthritis, uncontrolled hyper/hypothyroidism or hyper/hypoparathyroidism; 7. Uncontrolled concurrent diseases, including but not limited to: symptomatic congestive heart failure, hypertension (blood pressure remains > 150/90 mmHg after standard therapy), unstable angina, arrhythmia requiring medication or instruments, history of myocardial infarction within 6 months, echocardiography showing left ventricular ejection fraction <50%; 8. Active bacterial or fungal infections requiring systemic treatment within 7 days before randomization; 9. Known infection with human immunodeficiency virus (HIV), active infection with Hepatitis B virus (positive hepatitis B surface antigen and positive HBV-DNA) or Hepatitis C virus(positive hepatitis C surface antigen and positive HCV-RNA); 10. Pregnancy (serum ß-HCG positive) or lactation; 11. Use of any of the following anti-bone metabolism drugs within 6 months before enrollment: 1. parathyroid hormonerelated peptides 2. calcitonin 3. osteoprotegerin 4. mithramycin 5. strontium ranelate 12. Known sensitivity to narlumosbart, denosumab, calcium or vitamin D; 13. Any other factors not suitable for participation in this study that in the opinion of the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Narlumosbart
Administered by subcutaneous injection once every 4 weeks.
Denosumab
Administered by subcutaneous injection once every 4 weeks.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
RenJi Hospital Shanghai JMT-Bio Inc.

References & Publications (1)

Dhillon S. Narlumosbart: First Approval. Drugs. 2024 Jan;84(1):105-109. doi: 10.1007/s40265-023-01985-3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percent change from baseline in urinary N-terminal telopeptide of type 1 collagen corrected for urinary creatinine (uNTx/uCr) at week 13 Compare narlumosbart and denosumab for percentage change in bone turnover marker (BTM) - urinary N-terminal telopeptide of type 1 collagen (uNTx) corrected for urinary creatinine (uCr) (uNTx/uCr from baseline to week 13) From baseline to week 13
Secondary The proportion of subjects with a change in uNTx/uCr greater than 65% from baseline to week 13 Compare narlumosbart and denosumab for the proportion of subjects with a change in uNTx/uCr greater than 65% from baseline to week 13 (uNTx/uCr from baseline to week 13 >65%) From baseline to week 13
Secondary Time to first on-study skeletal related event A skeletal-related event (SRE) is defined as one of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE From baseline to 90 days after the last dose, up to approximately 30 months
Secondary Percentage of participants with an on-study SRE at different time points A skeletal-related event (SRE) is defined as one of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression.
Percentage of participants with an on-study SRE at 3, 6, 12, 18 and 24 months
Months 3, 6, 12, 18 and 24
Secondary Time to first and subsequent on-study SRE Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE.
Time to a subsequent SRE is defined, similarly to the time to first on-study SRE, as the time interval from the randomization date to the date of a subsequent occurrence of on-study SRE, which had to be at least 21 days after the previous SRE.
From baseline to 90 days after the last dose, up to approximately 30 months
Secondary Percent changes of serum bone alkaline phosphatase (BALP) and serum C-terminal telopeptide of type 1 collagen (sCTX-I) Compare the changes of BALP and sCTX-I from baseline to weeks 13 From baseline to week 13
Secondary Overall Survival Overall survival was defined as the time interval (in days) from the randomization date to the date of death. From baseline to 90 days after the last dose, up to approximately 30 months
Secondary Incidence and type of adverse events (AEs) To identify the incidence and the type of AEs, including abnormalities in clinical, laboratory assessments, ECGs, echocardiography, vital sign assessments, and physical exams. From the first dose finished to 28 days after the last dose
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1